Om

Ascendis Pharma A/S is a global biopharmaceutical company focused on developing and commercializing therapies for rare endocrine diseases and other serious chronic conditions. The company uses its proprietary TransCon technology platform to create medicines designed to improve treatment delivery and address unmet medical needs. Its current portfolio includes marketed products for growth hormone deficiency and chronic hypoparathyroidism, along with clinical-stage programs in endocrinology rare disease and oncology. Headquartered in Copenhagen, Denmark, Ascendis Pharma operates across Europe and the United States, combining research, development, and commercialization capabilities to support patients, physicians, and healthcare systems in specialized therapeutic areas.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I ASCENDIS PHARMA MED ENDAVU: Køb Ascendis Pharma ($A710) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Ascendis Pharma, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.